The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
Panelists discuss how prospective randomized data, notably from Hofman et al (Lancet, 2020), demonstrate that PSMA PET-CT exhibits superior diagnostic accuracy compared with conventional imaging in detecting pelvic nodal and distant metastases in patients with high-risk prostate cancer. Conventional imaging techniques, such as CT and bone scans, often have lower sensitivity and specificity, potentially missing smaller or early metastatic lesions. In contrast, PSMA PET-CT offers enhanced sensitivity and specificity, leading to more precise staging and management decisions.
Video content above is prompted by the following:
- What have prospective randomized data shown when comparing conventional vs PSMA-PET imaging, and how have these data influenced the current landscape? (Hofman et al. Lancet. 2020)
- What are some of the key limitations of conventional imaging techniques, and what key advantages does PSMA PET provide over conventional imaging?
- Briefly comment on the current NCCN guidelines regarding preferred imaging approaches in the diagnosis and management of prostate cancer. (NCCN Clinical Guidelines in Oncology. Prostate cancer, version 1.2025)
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
